title: Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
abstract: In this study, we used folic-acid-modified poly(ethylene glycol)-poly(lactic-co-glycolic acid) (FA-PEG-PLGA) to encapsulate cisplatin and paclitaxel (separately or together), and evaluated their antitumor effects against lung cancer; this study was conducted in order to investigate the antitumor effects of the co-delivery of cisplatin and paclitaxel by a targeted drug delivery system. Blood compatibility assays and complement activation tests revealed that FA-PEG-PLGA nanoparticles did not induce blood hemolysis, blood clotting, or complement activation. The results also indicated that FA-PEG-PLGA nanoparticles had no biotoxic effects, the drug delivery system allowed controlled release of the cargo molecules, and the co-delivery of cisplatin and paclitaxel efficiently induces cancer cell apoptosis and cell cycle retardation. In addition, co-delivery of cisplatin and paclitaxel showed the ability to suppress xenograft lung cancer growth and prolong the survival time of xenografted mice. These results implied that FA-PEG-PLGA nanoparticles can function as effective carriers of cisplatin and paclitaxel, and that co-delivery of cisplatin and paclitaxel by FA-PEG-PLGA nanoparticles results in more effective antitumor effects than the combination of free-drugs or single-drug-loaded nanoparticles.
authors.affiliation: The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan Western Road, Wenzhou, 325027, China.|Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
authors.forename: Zelai
authors.initials: Z
authors.lastname: He
authors.affiliation: Henan Polytechnic Institute, No 666, Kongming North Road, Nanyang Henan, 473000, China.
authors.forename: Zengfang
authors.initials: Z
authors.lastname: Shi
authors.affiliation: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Sun
authors.affiliation: Department of Ultrasound, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Nuclear Medicine, the Affiliated Provincial Hospital of Anhui Medical University, Hefei, 230001, China.
authors.forename: Junyong
authors.initials: J
authors.lastname: Xia
authors.affiliation: Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China. zhangxiangyu666@126.com.
authors.forename: Xiangyu
authors.initials: X
authors.lastname: Zhang
authors.affiliation: The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan Western Road, Wenzhou, 325027, China. cwj2233@126.com.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Chen
authors.affiliation: The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan Western Road, Wenzhou, 325027, China. 12211020053@fudan.edu.cn.
authors.forename: Jingwen
authors.initials: J
authors.lastname: Huang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001769:Blood / Q000187:drug effects*; D001777:Blood Coagulation / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D002460:Cell Line; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D003167:Complement Activation / Q000187:drug effects; D004337:Drug Carriers; D004339:Drug Compounding; D005492:Folic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*; D011091:Polyesters / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011817:Rabbits; D023041:Xenograft Model Antitumor Assays
chemical_list: D004337:Drug Carriers; D011091:Polyesters; C000589473:polyethylene glycol-poly(lactide-co-glycolide); D011092:Polyethylene Glycols; D005492:Folic Acid; D017239:Paclitaxel; D002945:Cisplatin
keywords: CDDP; Co-delivery; Lung cancer; Nanoparticles; PTX